Chromogranin A and neurone-specific enolase variations during the first three months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer

To determine the prognostic factors of circulating chromogranin A (CgA) and neurone-specific enolase (NSE) variations during the first 3 months of abiraterone Acetate (AA) treatment in metastatic castration-resistant prostate cancer (mCRPC) patients.

The serum levels of CgA, NSE were measured at baseline and after 3 months of AA treatments in 40 mCRPC patients. Outcome measures were PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS) and overall survival (OS).

CgA levels were not correlated with NSE levels (P=0.296). In multivariate analysis the combination of CgA and NSE (≥1 marker positive vs both markers negative) and combination of CgA and NSE elevation during the first 3 months of AA treatment (≥1 marker positive vs both markers negative) remained significant predictors of OS, rPFS, and PSA-PFS.

In our study, we observed that CgA and NSE elevation during the first 3 months of AA treatment and elevated baseline CgA and NSE levels were independent prognostic factors in OS, rPFS and PSA-PFS in mCRPC treated with AA. It is suggested that serial CgA and NSE evaluation would help clinicians in distinguishing the mCRPC patients who would obtain the best survival benefit from AA treatment. This article is protected by copyright. All rights reserved.

BJU international. 2017 Jan 20 [Epub ahead of print]

Liancheng Fan, Yanqing Wang, Chi Chenfei, Jiahua Pan, Xun Shangguan, Zhixiang Xin, Jianian Hu, Zhou Lixin, Baijun Dong, Wei Xue

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.